<DOC>
	<DOCNO>NCT00004986</DOCNO>
	<brief_summary>The purpose study see safe effective treat cryptosporidiosis AIDS patient nitazoxanide .</brief_summary>
	<brief_title>Safety Effectiveness Nitazoxanide Treatment Cryptosporidiosis AIDS Patients</brief_title>
	<detailed_description>Patients take nitazoxanide daily 8 week dose escalation first 4 week . Patients return hospital examination every 2 week 8-week treatment period 6-week follow-up . Nitazoxanide therapy discontinue patient show complete clinical parasitologic response ( therapeutic cure ) 8 week treatment patient show therapeutic cure two consecutive visit ( Weeks 2 4 Weeks 4 6 ) . These patient undergo physical examination include stool analysis Cryptosporidium parvum oocysts routine laboratory test Weeks 2 , 4 , 6 completion nitazoxanide therapy . Patients show complete clinical parasitologic response ( therapeutic failure ) 8 week treatment allow remain nitazoxanide therapy Open Label Compassionate Use Nitazoxanide Treatment Cryptosporidiosis AIDS Patients ( UMD-95-009 ) protocol .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cryptosporidiosis</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have CD4 cell count 50 cells/mm3 less . Have evidence cryptosporidium infection stool sample within 10 day study entry . Have watery stool least three time day least 5 day week 21 day prior enrollment . Are able take medication mouth . Are least 13 year old ( consent parent guardian require 18 ) . Agree use effective method birth control ( condom ) study . Exclusion Criteria Patients eligible : Have certain disease infection intestine . Have ever take nitazoxanide . Have take certain experimental drug within 14 day enrollment . Will need take certain medication study paromomycin , azithromycin , clarithromycin . Have start new antiHIV therapy within 4 week study entry plan start one study . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Cryptosporidiosis</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>Treatment Failure</keyword>
	<keyword>nitazoxanide</keyword>
</DOC>